| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | 31.45% | — | 1525.02% | -4154.64% | -282.44% | -4820.98% | -6599.22% | -1671.12% | — |
| EBITDA Margin | 32.18% | — | 1516.33% | -4114.34% | -257.86% | -4526.20% | -6219.99% | -1636.13% | — |
| Net Margin | 55.49% | — | 1698.41% | -156.02% | -281.90% | -4762.92% | -6237.45% | -1553.07% | — |
| Current Ratio | 4.85 | 4.97 | 7.25 | 8.02 | 11.14 | 9.69 | 21.54 | 8.72 | 14.85 |
| Quick Ratio | 4.85 | 4.97 | 7.25 | 8.02 | 11.14 | 9.69 | 21.54 | 8.72 | 14.85 |
| Debt / Equity | — | — | — | — | — | — | — | — | — |
| ROE | 70.98% | -841.11% | -154.76% | -2.81% | -56.45% | -65.66% | -40.20% | -29.38% | 76.02% |
| ROA | 48.27% | -51.70% | -133.58% | -2.19% | -45.23% | -48.80% | -33.46% | -22.08% | -21.81% |
| Asset Turnover | 0.87 | 0.00 | -0.08 | 0.01 | 0.16 | 0.01 | 0.01 | 0.01 | — |
| Book Value / Share | 3.41 | 0.59 | 1.26 | 3.10 | 3.07 | 4.27 | 6.14 | 6.82 | — |
Q32 Bio Inc. is a clinical-stage biotechnology company developing biologic therapeutics that target potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Its primary focus is on bempikibart (ADX-914), a fully human anti-IL-7Rα antibody designed to block signaling mediated by IL-7 and TSLP, thereby re-regulating adaptive immune function. This candidate is being evaluated in the ongoing Phase 2 SIGNAL-AA trial for alopecia areata, with enrollment completed in Part B and topline data anticipated in mid-2026. Previously, the company advanced ADX-097, a tissue-targeted complement inhibitor, through Phase 1 and into Phase 2 development for complement disorders before selling it to Akebia Therapeutics while retaining its underlying platform, including ADX-096 for potential ophthalmologic indications. Q32 Bio also maintains other C3d mAb fusions and nanobodies aimed at tissue-targeted complement inhibition. Headquartered in Waltham, Massachusetts and founded in 2017, Q32 Bio plays a role in the biotechnology sector by addressing unmet needs in immune-mediated conditions through innovative antibody-based therapies.